Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy ... febrile neutropenia (4%), anemia (2%), diarrhea (1%), maculopapular rash (1%), and vomiting (1%). Grade 4 effects were ...
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...